

# Brian A Bruckner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2520872/publications.pdf>

Version: 2024-02-01

41  
papers

1,619  
citations

331670

21  
h-index

330143

37  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2639  
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous Flow Left Ventricular Assist Devices: Shared Care Goals of Monitoring and Treating Patients. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 11, 33.	1.0	28
2	Delayed Type A Aortic Dissection Following Complete Debranching of the Aortic Arch and Stent Graft Placement. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 12, 45.	1.0	2
3	Cardiac Tumor Resection and Repair with Porcine Xenograft. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 12, 116.	1.0	9
4	Pulse assessment is important with blood pressure measurement in individuals with continuous flow left ventricular assist devices. <i>International Journal of Artificial Organs</i> , 2021, 44, 124-129.	1.4	2
5	Evaluation of the Safety and Efficacy of a Novel Thrombin Containing Combination Hemostatic Powder Using a Historical Control. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110172.	1.7	2
6	Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations. <i>Journal of Cardiac Surgery</i> , 2020, 35, 313-319.	0.7	13
7	Application techniques of a novel hemostat in cardiac operations: HEMOBLAST. <i>Journal of Cardiac Surgery</i> , 2019, 34, 849-853.	0.7	7
8	Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. <i>American Journal of Transplantation</i> , 2019, 19, 2900-2909.	4.7	11
9	Implication of Ventricular Assist Devices in Extracorporeal Membranous Oxygenation Patients Listed for Heart Transplantation. <i>Journal of Clinical Medicine</i> , 2019, 8, 572.	2.4	7
10	Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	31
11	Technologies for intrapericardial delivery of therapeutics and cells. <i>Advanced Drug Delivery Reviews</i> , 2019, 151-152, 222-232.	13.7	10
12	Back Cover Image: Volume 34 Issue 9. <i>Journal of Cardiac Surgery</i> , 2019, 34, ii.	0.7	0
13	Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation. <i>Journal of Clinical Investigation</i> , 2019, 129, 1984-1999.	8.2	47
14	Long-Term Survival in Bilateral Lung Transplantation for Scleroderma-Related Lung Disease. <i>Annals of Thoracic Surgery</i> , 2018, 105, 893-900.	1.3	22
15	Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 7-14.	0.6	35
16	Retransplantation Outcomes at a Large Lung Transplantation Program. <i>Transplantation Direct</i> , 2018, 4, e404.	1.6	24
17	A Multisite Randomized Controlled Trial of a Patient-Centered Ventricular Assist Device Decision Aid (VADDA Trial). <i>Journal of Cardiac Failure</i> , 2018, 24, 661-671.	1.7	30
18	Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 555.	2.8	21

#	ARTICLE	IF	CITATIONS
19	Caregivers of Patients With Left Ventricular Assist Devices. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	33
20	Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma. <i>Annals of Thoracic Surgery</i> , 2017, 104, 90-96.	1.3	92
21	Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 518-527.	4.1	159
22	A Rare Case of Left Atrial Hemangioma: Surgical Resection and Reconstruction. <i>Methodist DeBakey Cardiovascular Journal</i> , 2016, 12, 51-54.	1.0	6
23	Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L238-L254.	2.9	67
24	Altered Hypoxic Adenosine Axis and Metabolism in Group III Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 574-583.	2.9	41
25	Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience. <i>Annals of Thoracic Surgery</i> , 2016, 101, 698-702.	1.3	141
26	Persistent Blood Stream Infection in Patients Supported With a Continuous-Flow Left Ventricular Assist Device Is Associated With an Increased Risk of Cerebrovascular Accidents. <i>Journal of Cardiac Failure</i> , 2015, 21, 119-125.	1.7	85
27	MDCT Assessment of Mechanical Circulatory Support Device Complications. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 100-102.	5.3	14
28	Treatment Strategies for Patients with an Intermacs I Profile. <i>Methodist DeBakey Cardiovascular Journal</i> , 2015, 11, 4-8.	1.0	4
29	Left Ventricular Assist Device Implantation After Intracardiac Parachute Device Removal. <i>Annals of Thoracic Surgery</i> , 2015, 100, 720-722.	1.3	2
30	Blockade of IL-6 Signaling Attenuates Pulmonary Fibrosis. <i>Journal of Immunology</i> , 2014, 193, 3755-3768.	0.8	247
31	Safety and Efficacy of Ixmyelocel-T. <i>Circulation Research</i> , 2014, 115, 730-737.	4.5	56
32	Echocardiographic Evaluation of Hemodynamics in Patients With Systolic Heart Failure Supported by a Continuous-Flow LVAD. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1231-1241.	2.8	63
33	Autotransplantation for the Resection of Complex Left Heart Tumors. <i>Annals of Thoracic Surgery</i> , 2014, 98, 863-868.	1.3	68
34	Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures. <i>Journal of Cardiothoracic Surgery</i> , 2014, 9, 134.	1.1	48
35	Large Cardiac Tumor Managed With Resection and Two Ventricular Assist Devices. <i>Annals of Thoracic Surgery</i> , 2014, 97, 321-324.	1.3	13
36	Update on the Houston Methodist DeBakey Heart & Vascular Center Cardiac Stem Cell Studies. <i>Methodist DeBakey Cardiovascular Journal</i> , 2013, 9, 229-229.	1.0	0

#	ARTICLE	IF	CITATIONS
37	Microporous Polysaccharide Hemosphere Absorbable Hemostat (AristaAH <sup>®</sup> ) in Re-Operative Cardiac Surgical Procedures. <i>US Cardiology Review</i> , 2012, 9, 96-98.	0.5	0
38	High Incidence of Thromboembolic Events in Left Ventricular Assist Device Patients Treated With Recombinant Activated Factor VII. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 785-790.	0.6	52
39	Delayed left ventricular free-wall rupture after cardiac sarcoma resection. <i>Texas Heart Institute Journal</i> , 2009, 36, 171-3.	0.3	3
40	Clinical experience with the TandemHeart percutaneous ventricular assist device as a bridge to cardiac transplantation. <i>Texas Heart Institute Journal</i> , 2008, 35, 447-50.	0.3	48
41	Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 36-42.	0.6	76